Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × surufatinib × NET × Clear all

Status

Sponsor Class

Study Type

Interventional 8 Observational 1 Expanded_access 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumor Grade 3 1

Interventions

lutetium Lu 177 dotatate 6 Magnetic Resonance Spectroscopy 3 Data Collection 3 telotristat ethyl 2 Somatostatin 2 Everolimus 2 Biopsy 2 surufatinib 1 lanreotide 1 copper dotatate CU-64 1 Surveys and Questionnaires 1 Surgical Procedures, Operative 1 Sunitinib 1 Sorafenib 1 Salvage Therapy 1 Radionuclide Imaging 1 Radiomics 1 Radiofrequency Ablation 1 Positron-Emission Tomography 1 Plastic Surgery Procedures 1 Phlebotomy 1 Octreotide 1 Lutetium-177 1 Lutetium 1 Liver Transplantation 1 Laparoscopy 1 Electronic Health Records 1 Drug Therapy 1 Diet, Mediterranean 1 Cytidine Triphosphate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05973968 2023-08-04

Surufatinib in G3 Neuroendocrine Tumors

Qilu Hospital of Shandong University

Neuroendocrine Tumor Grade 3

Data powered by HemOnc (CC BY 4.0) Colophon ⚡